JN-International Medical Corporation

6912 North 97th Circle
United States of America, Nebraska

Phone: 402-884-3477
Fax: 402-614-4437
E-Mail: drreddy@jn-vaccines.orgThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it


Meningococcal meningitis VaccineJN developed low-cost Meningococcal meningitis (A,C,Y,W-135) polysaccharide vaccine for adults and Meningitis A,C,Y,W-135 Diphtheria conjugate meningococcal vaccine for children after successful completion of 52 weeks Phase-3 studies in Niger, Burkina Faso and Côte d’Ivoire or right on the Belt of Meningitis disease in West Africa. JN partnering with non-profit organizations, NGOs, local governments and communities in developing countries that address health issues facing underserved communities around the world. JN-International Medical Corporation opened its first overseas branch in 2005 in Abidjan, Côte d’Ivoire and later in 2006 in Ouagadougou, Burkina Faso. Operating in Africa enables the company to more efficiently store and distribute many of its products. By February 2007, the company plans to supply two million diagnostic tests for Malaria and TB to West Africa.

Malaria: JN markets the most acceptable malaria rapid diagnostic test kit in Africa, which detects the antigens of lactate dehydrogenase (pLDH) and can differentiate between malaria caused by P. falciparum and that caused by P. vivax, P. malariae, and P. ovale. This pLDH test has a sensitivity of 96% and a specificity of 98.5%, confirmed by Pasture Research Institutes in Ivory Coast and in Madagascar. The ability to accurately diagnose malaria is the first step in being able to help those infected.

The Tuberculosis epidemic is increasing the spread of multidrug-resistant strains of TB, which kills some 1,500 Africans every day. MDR-TB rates are rising in both Africa and parts of Eastern Europe. Africa is particularly hit because of co-infections with HIV and a lack of health infrastructure to monitor and treat the disease. Despite commendable efforts by countries and partners to control tuberculosis, their impact has not been significant and the epidemic has now reached unprecedented proportions.

JNI Medical Côte d’Ivoire, supplied one million Meningococcal meningitis A+C vaccine and one million Malaria, HIV and TB tests for screening and prevention in Ivory Coast, Burkina Faso, Niger, Mali, Senegal, Benin, Togo, Chad, Cameroon, Sierra Leone, Gambia, Ghana, Guinea, Mauritania and South Africa 2006-2007.